Patent ID: 11890324
Assignee: EPOQE PHARMA APS
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 5:
6. The method for treatment according to claim 1, wherein said CGRP compound is delivered in combination with one or more compounds selected from the group consisting of a beta blocker, a renin-angiotensin-system (RAS) inhibitor, an angiotensin 1 (AT1) blocker, a recombinant tissue plasminogen activator (TPA), an antithrombolytic, a new oral anticoagulant (NOAC), and an opioid,
wherein the beta blocker is metoprolol or propranolol,
wherein the RAS inhibitor is ramipril, enalapril, or captopril,
wherein the AT1 blocker is losartan, valsartan, or candesartan,
wherein the recombinant TPA is alteplase,
wherein the antithrombolytic is aspirin, heparin, warfarin, or clopidogrel,
wherein the NOAC is dabigatran, rivaroxaban, oxygen, or nitroglycerin, and
wherein the opioid is morphine.